Clinical Trials
105 trialsNCT05403541 2026-06-05
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Active not recruiting
NCT07217587 2026-06-05
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06392386 2026-06-04
ADAPT Jr SC
argenx
Phase 2/3 Recruiting
NCT07284420 2026-06-03
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
Phase 2 Recruiting
NCT07622342 2026-06-03
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2 Not yet recruiting
NCT06744920 2026-06-01
RELIEVE
Novartis
Phase 3 Recruiting
NCT06987539 2026-05-29
THYME
Amgen
Phase 2 Recruiting
NCT04980495 2026-05-27
ADAPT NXT
argenx
Phase 3 Completed
NCT06517758 2026-05-27
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
Phase 3 Recruiting
NCT06463587 2026-05-22
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3 Recruiting
NCT07039916 2026-05-22
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Recruiting
NCT07246564 2026-05-22
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 4 Recruiting
NCT07596784 2026-05-19
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Not yet recruiting
NCT07596901 2026-05-19
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Aurinia Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT06359041 2026-05-18
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Cabaletta Bio
Phase 1/2 Active not recruiting
NCT06680037 2026-05-18
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT07501702 2026-05-18
ETNA
Vertex Pharmaceuticals Incorporated
Phase 2 Recruiting
NCT04524273 2026-05-15
MINT
Amgen
Phase 3 Active not recruiting
NCT06193889 2026-05-15
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting
NCT06055959 2026-05-08
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06149559 2026-05-08
roMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06435312 2026-05-08
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
NCT06540144 2026-05-08
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Enrolling by invitation
NCT06456580 2026-05-07
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
Phase 3 Recruiting
NCT06447597 2026-04-30
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3 Recruiting
NCT07556120 2026-04-29
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1 Not yet recruiting
NCT05332210 2026-04-28
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 3 Completed
NCT04225871 2026-04-24
RAISE-XT
UCB Pharma
Phase 3 Active not recruiting
NCT05374590 2026-04-23
ADAPT Jr +
argenx
Phase 2/3 Enrolling by invitation
NCT05556096 2026-04-21
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07304154 2026-04-21
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
Phase 1 Recruiting
NCT05644561 2026-04-17
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT06414954 2026-04-13
SYNAPSE-MG
NMD Pharma A/S
Phase 2 Recruiting
NCT07221838 2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Recruiting
NCT07249632 2026-04-09
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT06704269 2026-04-06
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Novartis
Phase 1/2 Recruiting
NCT06607627 2026-04-01
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06471361 2026-03-27
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT06799247 2026-03-24
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Cartesian Therapeutics
Phase 3 Recruiting
NCT07463521 2026-03-17
MyVision
UCB Pharma
Phase 3 Not yet recruiting
NCT05265273 2026-03-13
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 2/3 Recruiting
NCT07465289 2026-03-11
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
UCB Pharma
Phase 3 Not yet recruiting
NCT04951622 2026-03-03
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06626919 2026-02-25
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Arcellx, Inc.
Phase 1 Recruiting
NCT04833894 2026-02-18
ADAPT Jr
argenx
Phase 2/3 Recruiting
NCT05070858 2026-02-12
NIMBLE
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06965309 2026-02-12
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase NA Terminated
NCT07250750 2026-02-11
Synergy-MG
ImmunAbs Inc.
Phase 1/2 Recruiting
NCT06220201 2026-02-10
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
NCT04818671 2026-01-22
ADAPTSC+
argenx
Phase 3 Completed